logo-loader
viewAmryt Pharma PLC

Holding(s) in Company

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Amryt Pharma PLC
GB00BKLTQ412
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)
Non-UK issuer 
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights 
An acquisition or disposal of financial instrumentsX
An event changing the breakdown of voting rights 
Other (please specify)iii: 
3. Details of person subject to the notification obligationiv
NameUBS Asset Management - O'Connor
UBS Group AG
City and country of registered office (if applicable)Zürich, Switzerland
4. Full name of shareholder(s) (if different from 3.)v
NameUBS O'Connor LLC
City and country of registered office (if applicable)Wilmington, USA
5. Date on which the threshold was crossed or reachedvi:7 October 2020
6. Date on which issuer notified (DD/MM/YYYY):9 October 2020
7. Total positions of person(s) subject to the notification obligation
 % of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached-6.12%6.12%162’801’593
Position of previous notification (if
applicable)
2.60%3.53%6.13% 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
shares

ISIN code (if possible)
Number of voting rightsix% of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BKLTQ412 - -
     
     
SUBTOTAL 8. A--
 

 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrumentExpiration
date
x
Exercise/
Conversion Period
xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
US03217L1061  9’967’6206.12%
     
     
  SUBTOTAL 8. B 19’967’6206.12%
 

 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrumentExpiration
date
x
Exercise/
Conversion Period
xi
Physical or cash
settlementxii
Number of voting rights % of voting rights
      
      
      
   SUBTOTAL 8.B.2  
 

 

 


9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii 
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
X
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
UBS Group AG   
UBS AG   
UBS Americas Holding LLC   
UBS Americas Inc   
UBS Asset Management (Americas) Inc   
UBS O'Connor LLC-6.12%6.12%
    
    
    


 
10. In case of proxy voting, please identify:
Name of the proxy holder 
The number and % of voting rights held 
The date until which the voting rights will be held 
 

 

 

 

 
11. Additional informationxvi
 


Place of completionOpfikon, Switzerland
Date of completion09.10.2020

Quick facts: Amryt Pharma PLC

Price: 196

Market: AIM
Market Cap: £319.09 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Amryt Pharma reports record Q3 2020 results, delivering 19% year on year growth

Amryt Pharma's LON:AMYT) Joe Wiley talks to Proactive New York's Christine Corrado about their latest record Q3 2020 Results. The results have lead to the full year guidance being raised which Wiley puts down to two launched commercial assents, metreleptin and lomitapide. Wiley talks...

4 weeks, 1 day ago